Cellecta



Cellecta, Inc. was founded in April 2006 by one of the chief scientists at Clontech Laboratories. The company was borne out of the need for higher quality, more advanced shRNA and peptide libraries. Today, our mission is to develop advanced high-throughput (HT) genetic screen and other next-generation technologies for the discovery and functional characterization of novel biomarkers and therapeutic targets. Today, Cellecta offers numerous off-the shelf assay kits as well as the highly customizable contract research services using advanced lentiviral technology for which we are renowned. Ou.... Read more

The DriverMap™ Human Genome-Wide Targeted Expression Profiling Assay enables resear...

Cellecta’s LINE-1 Assay Kit provides a convenient, efficient, and targeted Next-Gen...

Want to know if Cas9 is active in your cells? Cellecta’s CRISPRtest™ method allows ...

Cellecta’s Ready-to-Use Lentiviral Packaging Plasmid Mix allows the production of ...

LentiFuge™ viral concentration provides a simple, rapid, and effective method to in...

Cellecta, Inc. was founded in April 2006 by one of the chief scientists at Clontech Laboratories. The company was borne out of the need for higher quality, more advanced shRNA and peptide libraries. Today, our mission is to develop advanced high-throughput (HT) genetic screen and other next-generation technologies for the discovery and functional characterization of novel biomarkers and therapeutic targets.
Today, Cellecta offers numerous off-the shelf assay kits as well as the highly customizable contract research services using advanced lentiviral technology for which we are renowned. Our portfolio includes custom and off-the-shelf, genome-wide, pooled lentiviral shRNA and CRISPR libraries for any set of genes in any lentivector; RNAi and CRISPR genetic screens with pooled lentiviral shRNA and sgRNA libraries; reporter cell line development for genetic screens; bioinformatic data analysis for RNAi genetic screens; custom stable cDNA overproducer, shRNA expression knockdown cell lines, CRISPR knockout cell lines; and next-generation sequencing (NGS) kits and services. The company launched Driver-Map™ Human Genome-Wide Gene Expression Profiling assay, an ultra-sensitive yet simple targeted expression profiling solution that allows researchers a high-resolution molecular snapshot of their samples of interest. Key applications of this targeted RNA expression profiling approach include biomarker discovery, tumor cellular composition analysis and profiling of patient-derived xenograft (PDX) models. The Driver-Map assay technology is available today as an assay kit or as a service.
With over 10 years of experience in gene functional analysis, in collaboration with leading researchers in industry and academia, and with funding from over a dozen grants from the U.S. National Institutes of Health (NIH), our scientists have developed the most advanced functional genomic technologies commercially available today. Although we remain a small private company, Cellecta has important collaborations with important institutions such as the Roswell Park Cancer Institute, Fred Hutchinson Cancer Research Center (FHCRC), The Scripps Research Institute (TSRI), Cleveland Biolabs, Harvard School of Public Health, McGill University, Tufts University, and Health Research, Inc.
Headquartered in Mountain View, California, in the heart of Silicon Valley, Cellecta is located near some of the world’s leading biotech companies and research universities including Genentech, Stanford University, and the University of California campuses at Berkeley and San Francisco. For more information and to learn how Cellecta can help your drug discovery efforts, contact us at info@cellecta.com or at +1-650-938-3910